Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 5Breast Neoplasms 4Stomach Neoplasms 3Malnutrition 3Head and Neck Neoplasms 3Colonic Neoplasms 3Wilms Tumor 1Sarcoma 1Prostatic Neoplasms 1Prostatic Intraepithelial Neoplasia 1Peripheral Nervous System Diseases 1Peptic Ulcer 1Pancreatic Neoplasms 1Osteoporosis 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Myocardial Ischemia 1Mucositis 1Motor Activity 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia 1Kidney Neoplasms 1Inflammatory Bowel Diseases 1Hyperphagia 1Hepatitis C, Chronic 1Hematologic Neoplasms 1Heart Diseases 1

Interventions

ledipasvir, sofosbuvir drug combination 2ledipasvir 2Ribavirin 2peginterferon alfa-2a 1daclatasvir 1Viusid 1Sofosbuvir 1Simeprevir 1Introns 1Dietary Supplements 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hepatitis C, Chronic × Dietary Supplements × Clear all
NCT00502086 2011-02-11

Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.

Catalysis SL

Phase 3 Completed
100 enrolled
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡